Literature DB >> 34816327

PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.

Ju Zhou1, Saber Imani1, Marzieh Dehghan Shasaltaneh2, Shuguang Liu1, Tao Lu3, Junjiang Fu4.   

Abstract

BACKGROUND: Nigella sativa (N. sativa) exhibits anti-inflammatory, antioxidant, antidiabetic, antimetastatic and antinociceptive effects and has been used to treat dozens of diseases. Thymoquinone (TQ) is an important and active component isolated from N. sativa seeds. Inhibition of cancer-associated activating PIK3CA mutations is a new prospective targeted therapy in personalized metastatic breast cancer (MBC). TQ is reported to be an effective inhibitor of the PI3K/Akt1 pathway in MBC. This study aimed to evaluate the in vitro antitumor effect of TQ in the context of two PIK3CA hotspot mutations, p. H1047R and p. H1047L. METHODS AND
RESULTS: Molecular dynamics, free energy landscapes and principal component analyses were also used to survey the mechanistic effects of the p. H1047R and p. H1047L mutations on the PI3K/Akt1 pathway. Our findings clearly confirmed that the p. H1047R and p. H1047L mutants could reduce the inhibitory effect of ΔNp63α on the kinase domain of PIK3CA, resulting in increased activity of PI3K downstream signals. Structurally, the partial disruption of the interaction between the ΔNp63α DNA binding domain and the PIK3CA kinase domain at residues 114-359 and 797-1068 destabilizes the conformation of the activation loop and modifies the PIK3CA/ΔNp63α complex. Alongside these structural changes, we found that TQ treatment resulted in high PI3K/Akt1 pathway inhibition in p. H1047R and p. H1047L-expressing cells versus wild-type cells.
CONCLUSIONS: These two PIK3CA hotspot mutations therefore not only contribute to tumor progression in patients with MBC but may also serve as targets for the development of novel small molecule therapeutic strategies.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Breast cancer; Hotspot mutations; Molecular dynamics simulation; PIK3CA gene; Thymoquinone

Mesh:

Substances:

Year:  2021        PMID: 34816327     DOI: 10.1007/s11033-021-06990-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  50 in total

Review 1.  The phosphoinositide 3-kinase pathway.

Authors:  Lewis C Cantley
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

Review 2.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

3.  Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.

Authors:  Jingliang Cheng; Shangyi Fu; Chunli Wei; Mousumi Tania; Md Asaduzzaman Khan; Saber Imani; Baixu Zhou; Hanchun Chen; Xiuli Xiao; Jingbo Wu; Junjiang Fu
Journal:  Cancer Biomark       Date:  2017       Impact factor: 4.388

Review 4.  Thymoquinone and its therapeutic potentials.

Authors:  Sara Darakhshan; Ali Bidmeshki Pour; Abasalt Hosseinzadeh Colagar; Sajjad Sisakhtnezhad
Journal:  Pharmacol Res       Date:  2015-03-28       Impact factor: 7.658

Review 5.  Immunomodulatory and anti-inflammatory action of Nigella sativa and thymoquinone: A comprehensive review.

Authors:  Amin F Majdalawieh; Muneera W Fayyad
Journal:  Int Immunopharmacol       Date:  2015-06-26       Impact factor: 4.932

Review 6.  Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics.

Authors:  Md Asaduzzaman Khan; Mousumi Tania; Junjiang Fu
Journal:  Drug Discov Today       Date:  2019-09-18       Impact factor: 7.851

7.  Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation.

Authors:  Hideki Yamaguchi; Shuhei Yoshida; Emi Muroi; Nachi Yoshida; Masahiro Kawamura; Zen Kouchi; Yoshikazu Nakamura; Ryuichi Sakai; Kiyoko Fukami
Journal:  J Cell Biol       Date:  2011-06-27       Impact factor: 10.539

8.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

Authors:  Bernard Pereira; Suet-Feung Chin; Oscar M Rueda; Hans-Kristian Moen Vollan; Elena Provenzano; Helen A Bardwell; Michelle Pugh; Linda Jones; Roslin Russell; Stephen-John Sammut; Dana W Y Tsui; Bin Liu; Sarah-Jane Dawson; Jean Abraham; Helen Northen; John F Peden; Abhik Mukherjee; Gulisa Turashvili; Andrew R Green; Steve McKinney; Arusha Oloumi; Sohrab Shah; Nitzan Rosenfeld; Leigh Murphy; David R Bentley; Ian O Ellis; Arnie Purushotham; Sarah E Pinder; Anne-Lise Børresen-Dale; Helena M Earl; Paul D Pharoah; Mark T Ross; Samuel Aparicio; Carlos Caldas
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

9.  Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition.

Authors:  Md Asaduzzaman Khan; Mousumi Tania; Chunli Wei; Zhiqiang Mei; Shelly Fu; Jingliang Cheng; Jianming Xu; Junjiang Fu
Journal:  Oncotarget       Date:  2015-08-14

Review 10.  Review on the Potential Therapeutic Roles of Nigella sativa in the Treatment of Patients with Cancer: Involvement of Apoptosis: - Black cumin and cancer.

Authors:  Hamid Mollazadeh; Amir R Afshari; Hossein Hosseinzadeh
Journal:  J Pharmacopuncture       Date:  2017-09-30
View more
  3 in total

Review 1.  Anticancer Effect of Spices Used in Mediterranean Diet: Preventive and Therapeutic Potentials.

Authors:  Wamidh H Talib; Mallak J AlHur; Sumaiah Al Naimat; Rawand E Ahmad; Arkan Hadi Al-Yasari; Anfal Al-Dalaeen; Samar Thiab; Asma Ismail Mahmod
Journal:  Front Nutr       Date:  2022-06-14

Review 2.  Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis.

Authors:  Mina Homayoonfal; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-03-02       Impact factor: 5.787

3.  COVID-19 receptor and malignant cancers: Association of CTSL expression with susceptibility to SARS-CoV-2.

Authors:  Lianmei Zhang; Chunli Wei; Dabing Li; Jiayue He; Shuguang Liu; Haoyue Deng; Jingliang Cheng; Jiaman Du; Xiaoyan Liu; Hanchun Chen; Suan Sun; Hong Yu; Junjiang Fu
Journal:  Int J Biol Sci       Date:  2022-03-06       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.